Geoff Oxnard
Net worth: 331 512 $ as of 30/09/2026
Net worth: 331 512 $ as of 30/09/2026
Geoff Oxnard is Chief Medical Officer & Executive Vice President at Blossomhill Therapeutics, Inc. since 2025.
Formerly, Dr. Oxnard was Vice President & Global Head-Thoracic Cancers at Eli Lilly & Co. from 2023 to 2025 and Senior Vice President & Head-Clinical Development at F.
Hoffmann-La Roche Ltd. from 2021 to 2023.
Education includes undergraduate studies at Harvard University and a doctorate from Pritzker School of Medicine.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 07/08/2026 | 17,785 ( 0.06% ) | 331 512 $ | 30/09/2026 |
| Companies | Position | Start |
|---|---|---|
| BLOSSOMHILL THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2025 |
| Companies | Position | End |
|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/01/2025 |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 01/09/2023 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pritzker School of Medicine
Pritzker School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blossomhill Therapeutics, Inc.
Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for oncology and autoimmune diseases | Health Technology |
Select your edition
All financial news and data tailored to specific country editions